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Abstract 
Cisplatin,	  one of the most popular chemotherapeutic drugs on the market today, battles 
cancer by binding to DNA, and causing kinks which obstruct DNA replication and transcription. 
As a result, cisplatin halts cell proliferation of not only fast-dividing cancerous cells but healthy 
cells as well. To circumvent the shortcomings of cisplatin, the Anderson lab has synthesized a 
class of ruthenium (III)/ ferrocene compounds, named the RuLX series. These new hetero-
multinuclear complexes may have greater selectivity between cancerous and healthy cells 
through a proposed synergistic mechanism of their metal centers. Previous work on these novel 
complexes has demonstrated that they interact with DNA and proteins, suggesting that they may 
share similar molecular targets as cisplatin. RNA has merged as a new molecular target for metal 
therapeutics not only due to its chemical similarity with DNA, but also due to its essential role in 
cellular function. Many metallochemotheraputics target RNA as well as other biomolecules in 
their mode of action.  
The in vitro binding affinity of the RuLX complexes with RNA was investigated using a 
504-base RNA encoding the dihydrofolate reductase enzyme. Evidence suggests that RuL2 and 
RuL3 have a stronger binding affinity to RNA than RuL1. Moreover, in vitro translation of the 
DHFR mRNA was carried out to observe the potential downstream effects of these interactions.  
All three complexes exhibited a dose-dependent reduction of DHFR enzyme activity. 
Investigations with RuL2 specifically, suggest that its inhibition of DHFR activity is likely due 
to the metal complex binding to RNA. Explorative controls show that RuL2 does not 
significantly inhibit enzyme activity or ribosomal protein activity. 
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1. Introduction 
 
1.1 Cancer 
 Cancer, one of the leading causes of death worldwide, is characterized by uncontrolled 
cellular proliferation and avoidance of programmed cell death, or apoptosis1. According to 
Hanahan and Weinberg, cancer can be categorized by monitoring the hallmark differences that 
cancerous cells develop in comparison to healthy cells. Cancerous cells develop an extensive list 
of capabilities that enable their survival and proliferation throughout an organism. These 
acquired capabilities include the ability to be self-sufficient in the production and utilization of 
growth signals, an insensitivity to antigrowth signals, a cunning evasion of apoptosis, an almost 
limitless replicative potential, a sustained ability to form new blood vessels from old ones 
(angiogenesis), an ability to invade new tissues, and metastasis2. Cancer malignancy begins 
when cancerous cells gain the potential to metastasize, spreading to distant areas of the body 
through the circulatory and lymphatic system2. Cancerous cell’s ability to invade surrounding 
tissue, colonize, and destroy other tissues throughout the body has been tied to their cellular 
motility3. Due to robust research in the field, additional enabling traits that help cancer cells 
survive have been stipulated. These traits include the reprogramming of energy harvesting 
mechanisms to require low oxygen intake, the ability of cancerous cells to evade destruction 
from the immune system, and the development of tumor-promoting inflammation4. The 
discoveries of these additional mechanisms that aid in cancer malignancy have been the focus of 
current anti-cancer therapeutic research. 
Cancer arises as a result of somatic mutations in which genes that become mutationally 
under-expressed or abnormally overexpressed contribute to tumor formation, and are called 
protoconcogenes5. Moreover, healthy cells can become cancerous through spontaneous or 
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inherited mutations in tumor suppressor genes, which are genetic suppressors of tumor growth, 
mutations in oncogenes, which are genes that have the potential to promote cancerous growth, or 
other somatic mutations that give rise to oncogenes5. 
Cancers come in diverse physiological and chemical make-up. Fittingly, different modes of 
treating the disease have been developed. Some of the commonly used treatments in human 
cancers include: surgery, radiation therapy, immunotherapy, stem cell transplants and 
chemotherapy6. First, surgery combats cancer by excising the malignancy out of the body; it 
is particularly good at combating benign (non-metastasized) cancerous growth6. Second, 
radiation therapy uses high-energy radiation to target and destroy cancer cells6. Radiation 
therapy is one of the most common methods of cancer treatment out there today6. Third, 
immunotherapy, one of the lesser common cancer treatment methods, involves stimulating the 
immune system to work more efficiently in destroying cancer cells6. It may also involve 
supplying the immune system with synthesized proteins to stimulate anticancer activity6. Fourth, 
stem cell transplants entail a full transplantation of a person’s peripheral blood, bone marrow, 
and cord blood6. This treatment is particularly useful in combating cancers that affect the 
circulatory and lymphatic system6.  
Finally, the most widely known treatment method for cancer, chemotherapy, involves the 
administration of combinatorial drugs, usually intravenously, to combat the growth and spread of 
cancer cells6. Targeted therapy, which involves the use of chemicals more specifically tailored 
for cancerous cells in order to lessen the collateral destruction of healthy cells, is also an option 
for persons affected with cancer6. All of the aforementioned treatments are often used 
synergistically with each other, depending on the particular cancer type, to effectively destroy 
the cancerous cells. 
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1.2 Chemotherapy complex: Cisplatin  
1.2.1 Discovery of cisplatin 
 Cis-diaminedichloroplatinum(II), or 
cisplatin is a platinum based compound 
commonly used as a chemotherapy drug. It was 
discovered by, Barnett Rosenberg, a 
biophysicist at the University of Michigan, who 
at the time, was examining the impact of 
electrical current in cell division of Escherichia coli (E. coli)7,8. Unexpectedly, Rosenberg et al. 
found that interaction of the platinum electrodes and the ammonium chloride buffer caused 
filamentous growth and the inhibition of cell division in E. coli7.8. Since the platinum species 
proved to be potent in inhibiting bacterial cell division, it was reasoned that the platinum species 
might offer similar antiproliferation mechanisms when tested on rapidly dividing cancerous cells. 
In order to test the anticancer potential of their platinum species, Rosenberg et al. tested cisplatin, 
and ten other group 10 transition metal complexes, on small solid sarcoma 180 tumors in mice8,9.  
They found that cisplatin, and some analogs, completely inhibited the development of tumor 
growth if administered one day after tumor inoculation in mice.  It also yielded impressive 
results when it was tested on different cancer types using different animal models9.  Cisplatin's 
effectiveness in combatting cancer led the FDA to approve it for clinical applications in 197810. 
Cisplatin is so potent in combatting cancer that it still boasts a greater than ninety percent cure 
rate for promptly diagnosed testicular cancer10.  
 
1.2.2 Cisplatin’s mechanism of action 
Pt
Cl NH3
NH3Cl
Figure 1: The chemical structure of 
cisplatin. 
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Much of cisplatin’s possible mechanisms of action have been elucidated after its clinical 
approval due to the emergence of metallochemotherapeutic research. Cisplatin primarily enters 
the cell through passive diffusion and active transport mediated by the transporter protein 
Ctr1p10,13. The low intracellular chlorine ion concentration of the physiological environment 
facilitates the hydrolysis and activation of the cisplatin complex into its aquatic form, 
[Pt(NH3)2Cl(OH)2]+ and [Pt(NH3)2(OH2)2]2+ 10. In its active form, cisplatin can react easily with 
cellular components such as DNA, RNA, proteins and membrane phospholipids13. Although 
cisplatin can react with many cellular components, DNA is believed to be its primary target.  
Cisplatin binds to DNA by forming inter-strand and intra-strand adducts with the N7 atom of 
purine bases11. 
 
 
In the aquated form of cisplatin, the weakly bound hydroxide ligand is easily displaced, 
allowing the platinum center to coordinate to the N7 nitrogen of the purine bases and form 
Figure 2: Mechanism of action of cisplatin anti-cancer activity by binding with DNA12 
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covalent bonds11. This results in primarily 1,2 or 1,3-intrastrand crosslinks and a lower number 
of inter-strand crosslinks11. The major adducts formed from cisplatin binding are GpG (40-50%) 
and ApG (23-38%) intrastrand crosslinks as well as interstrand crosslinks accounting for 1-7% of 
adduct formation14. The N7 nitrogen is the most accessible atom for cisplatin coordination 
because it is not only located in the major groove of the DNA helix, but it also possesses a lone 
pair available for coordination. Once bonded, cisplatin causes a major structural distortion of the 
DNA double helix, disrupts base pairing, and widens the minor groove. Cisplatin binding 
produces a rigid bend in DNA of 30-35° directed toward the major groove and a localized 
unwinding of the DNA helix of 13° 14. As a result, essential biological functions including DNA 
repair, replication and transcription are inhibited15. The Pt-DNA adducts additionally activate 
several signal transduction pathways including ART, p53, p73 and MAPK which consequently 
activate apoptosis15. Sometimes, cisplatin damaged DNA elicits cellular repair mechanisms. If 
these repairs are unsuccessful, apoptosis is activated to terminate the cell. Cisplatin has also been 
shown to hinder mRNA from directing in vitro peptide synthesis by preventing the formation of 
the complete translation initiation complex16, 17. Nevertheless, it is cisplatin’s binding to DNA 
that is credited as the mode of action due to which the proliferation of cells is inhibited.  
 
1.2.3 Cisplatin’s shortcomings 
Although cisplatin can boast great clinical success, it does come with some potent 
drawbacks. One of which is the unselective cytotoxicity that cisplatin bears to both healthy and 
cancerous cells which causes severe side effects10. These include damage to nearby convoluted 
tubes of the kidney, extreme nausea and intense vomiting9.  Moreover, although it was expected 
for some tissues to bear spontaneous resistance to cisplatin, recent research has revealed that 
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tissues can develop cisplatin resistance over time. The mechanisms by which cells resist 
cisplatin-induced cytotoxicity include reduced cellular uptake of cisplatin, the ability to 
chemically inactivate the compound and DNA adduct repair18. Reduced cisplatin accumulation 
in resistant cells is due to an inhibition in cellular uptake or an increase in drug efflux, or both18. 
The inactivation of cisplatin has been attributed to the non-enzymatic and rate-limiting 
interactions between aquated cisplatin and endogenous nucleophiles such as glutathione, 
methionine, metallothionein and several proteins18. DNA adduct repair via the nucleotide 
excision repair mechanism reduces the number of Pt-DNA adducts and as a result, reduces the 
cascading of the apoptotic signal18. Furthermore, cisplatin is not active against all primary 
tumors. Notable exceptions include breast cancer, prostate cancer and colorectal cancers20. It is 
also minimally effective in combatting metastatic cancer due to its mostly cytotoxic mechanism 
of action20. As cancers become more resistant to common chemotherapeutic drugs like cisplatin, 
and other platinum centered drugs, a focus in biomedical research has centered on developing 
new organometallic complexes to circumvent the shortcomings of cisplatin.   
 
1.3 Ruthenium complexes 
1.3.1 Prodrug selectivity 
 In organometallic research, ruthenium complexes have gained popularity as potential 
chemotherapeutics due to their unique reactivity. Ruthenium (III) complexes modeled after 
cisplatin have demonstrated antitumor properties and lower cytotoxicity than cisplatin. The 
octahedral geometry of ruthenium (II) and (III) complexes, as opposed to the square planar 
geometry of cisplatin, lends evidence to the hypothesis that ruthenium complexes function 
differently from platinum complexes21. For instance, while adjacent intra-strand G-G crosslinks 
with cis-Ruthenium ions are possible, they are sterically more hindered due to its octahedral 
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geometry21. Moreover, research suggests that Ru (III) complexes function as a prodrug and work 
by ‘activation by reduction’ mechanism. Ru (III) complexes are activated by their in 
vivo reduction into the chemically active Ru (II)  in order to more effectively coordinate to 
biomolecules21. The lower charge and the reduced π-bonding effects of Ru (II) that make Ru (II) 
more reactive than Ru(III) 21. Moreover, the hypoxic and acidic microenvironment of tumor cells 
caused by excess lactic acid creates a low electrochemical potential inside the cell that allows for 
Ru(III) to be reduced to Ru(II) selectively in tumor tissue21. Lactic acid accumulation comes 
about due to low intracellular oxygen content, which is caused by the lag between the rate of 
angiogenesis and the rate of cell growth and division2. As the rate of cancerous cell division 
increases, this causes a build-up of tumor tissue that is ineffectively vascularized and as a result, 
hypoxic. Until the rate of angiogenesis catches up to the rate of cancerous cell growth and 
division, the tumor tissue microenvironment remains hypoxic13. Hence, the higher Ru(II) 
compared to Ru(III) concentration in cancerous cells coupled with the inherently higher 
reactivity of Ru(II) is thought to make ruthenium based prodrugs somewhat more selective 
towards cancerous cells. 
 
1.3.2 New Anti-tumor Metastasis Inhibitor (NAMI) and its analog NAMI-A 
 Early ruthenium anticancer compounds, which included: cis- and trans-[RuCl(DMSO)] 
complexes,  paved the way for the design of current clinically used ruthenium based prodrugs 
like Na{trans-[Cl4(DMSO)(Im)Ru]}, known as NAMI  and its analog, Na{trans-
Cl4(DMSO)(Im)Ru]}, also known as NAMI-A22. Because these ruthenium complexes can lose 
both their chloride and DMSO ligands, the mode with which they bind to biomolecules is more 
flexible than cisplatin23. Heterocyclic additions, such as imidazole and indazole, to ruthenium-
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based drugs have also shown to have positive impacts on their anti-proliferation properties19. 
NAMI is active against a broad range of tumors including Lewis lung carcinoma, B16 
melanoma, and MCa mammary carcinoma23. Notably, research has found that only a very low 
fraction of the NAMI reaches the tumor target23. In addition, its activity appears to be 
independent of its concentration in tumor cells, and its major mechanism of action does not 
involve DNA binding23.  
 Rather than cytotoxicity, NAMI combats cancer by increasing the resistance to the 
formation of tumor metastases. It accomplishes this without enhanced antigenicity or instigating 
immunological responses23. NAMI is also credited with down regulating type-IV collagenolytic 
activity and metastatic potential of MCa mammary carcinoma. NAMI significantly increases the 
mRNAs of MMP-2, a metalloproteinase capable of degrading the extracellular matrix, and 
TIMP-2, the specific tissue inhibitor of the aforementioned enzyme at dosages that prevent 
metastasis in lung cancer23. This causes a pronounced increase of extracellular matrix 
components in the tumor parenchyma and around tumor blood vessels; excess extracellular 
matrix components are thought to hinder both metastasis formation and blood flow to the 
tumor23.  
 NAMI-A, a chemical analog of NAMI 
where the sodium counter-ion is replaced with an 
imidazolium ion, also boasts antimetastatic 
properties. In vitro, NAMI-A has comparable 
binding affinity to DNA as cisplatin24. However, 
in vivo studies using four different tumor cell lines 
revealed that NAMI-A has a much lower affinity 
N
HN
Ru
Cl Cl
ClCl
S O
NH
H
N
Figure 3:Chemical structure of 
NAMI-A 
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to DNA than cisplatin24. NAMI-A-induced DNA kinks were only detected at extremely high 
dosages compared to cisplatin. Moreover, the frequency of NAMI-A's Ru-GG and Ru-AG 
intrastrand adducts to DNA are meek compared to the more plentiful cisplatin intrastrand 
adducts25. It is unsurprising that the lower rate of NAMI-A's cellular cytotoxicity was attributed 
to its lower intrastrand adduct formation24. However, NAMI-A is capable not only of preventing 
the formation of tumor metastases but also, of inhibiting their growth in a similar fashion to 
NAMI. 
 
1.4 Ferrocene complexes 
 Another class of metal complexes that have been shown 
to exhibit antineoplastic effects are iron-containing compounds. 
In particular, ferrocene−a compound containing two π-bonded	  
cyclopentadienyl ligands on an iron molecule. This compound’s 
medicinal properties were first investigated because it was the 
first iron-containing compound found to exhibit antiproliferative 
properties27. Ferrocene complexes differ from platinum or 
ruthenium complexes in three major ways. Firstly, the central 
iron atom exists in the oxidation state +2 in ferrocene and the oxidation state +3 in ferrocenium 
ions28. Secondly, they lack any cis-halide ligands able to be dissociated24. Thirdly, they contain 
two cyclopentadienyl rings in a sandwiched arrangement; the central iron is tightly bound and is 
unlikely participate in further coordination bonds28.  
 Moreover, ferrocene bears little cytotoxicity. In murine model experiments, it was shown 
that orally administered ferrocene is not only non-toxic, but it is degraded (enzymatically 
Fe
ferroceneFigure 4: The chemical structure of 
ferroccene. 
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hydroxylated) in the liver and excreted in urine11. Ferrocene can additionally undergo a one-
electron oxidation to give the ferrocenium cation. This cation is easily soluble due to its salt-like 
qualities. It is also relatively stable and the redox reaction from which it was generated is also 
reversible11. The ferrocenium salt-like cations exhibited antineoplastic activity against Ehrlich 
ascites tumor (EAT) cell lines in CF1 mice, which are very resistant to classical antitumor agents 
such as platinum centered metal complexes27. While they found that the ferrocene complex itself 
bears no recognizable antitumor effects on these cells lines, they found that ferrocenium salt-like 
complexes boast incredible inhibitory effects, with some 100% cure rates of tumors27. Other 
ferrocene derivatives have shown significant anticancer potential, for instance that of tamoxifen 
and its derivatives. Tamoxifen is the front-line chemotherapeutic agent for patients with 
hormone-dependent breast cancer. Its active metabolite is hydrotamixifen. Tamoxifen combats 
breast cancer by competitively binding to the ERα subtype and repressing estradiol-mediated 
DNA transcription in the tumor tissue11.  
 
 Although the mechanism of action of these ferrocenium salts has yet to be elucidated, it is 
proposed that their cytotoxic activity is not based on their direct linking to DNA, but rather 
	  
Figure 5: The chemical structure of A) Ferrotamoxifen and B) Ferro-hydrotamoxifen.11 
A) B) H
O(CH2)2N(CH3)2
Fe Fe
OH
O(CH2)2N(CH3)2
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on their ability to generate oxygen active species that induce oxidative DNA damage24. It is 
thought that ferrocenium cations generate hydroxyl radicals in physiological conditions that 
damage DNA via fenton-type reactions28. The tumor microenvironment, which contains 
increased concentrations of hydrogen peroxide, allows for the production of these radicals. 
 Un-substituted ferrocene is insoluble in water; it is unsurprising that it does not display 
any tumor inhibiting activity. However, once inserted into the target cells, it could interconvert to 
the ferrocenium cation, and vice versa, depending upon the redox potential of the tumor 
microenvironment28. Hence, much like the ruthenium containing complexes, ferrocenium salts 
have the potential to selective target cancerous cells while causing little harm to healthy cells.  
 
1.5 Multinuclear compounds 
 To circumvent cellular resistance to cisplatin, multiplatinum complexes modeled after 
cisplatin were developed14. These complexes bound to DNA in a similar manner to cisplatin. 
However, due to their larger size and varied ligands, these multiplatinum complexes were able to 
form non-directional DNA adducts, to form a greater number of interstrand adducts compared to 
cisplatin, and to induce conformational type changes to both A- and Z-type DNA14. It has been 
suggested that DNA repair proteins weakly recognize DNA adducts resultant from multiplatinum 
complexes because of their different characteristics compared to cisplatin induced DNA adducts. 
Consequently, the structural changes caused by multiplatinum complexes bypass recognition 
from DNA repair proteins and more successfully, inhibit DNA transcription and replication14.  
 Moreover, due to the discovered anticancer potential of different transition metal 
complexes, recent research has sought to combine different metal centers into one complex that 
would posses the best qualities of all its components. Some mixed-metal species that has 
afforded some success in heteromultinuclear antineoplastic research are a series of complexes 
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that couple a light absorbing ruthenium (II) or osmium (II) metal center to a reactive platinum 
site that contains the cis-dichloride platinum moiety. This moiety is through to be responsible for 
cisplatin’s anticancer activity 29-31.  Brewer and colleagues found that their novel complexes 
awarded a higher percentage of interstrand crosslinks compared to cisplatin. Furthermore, 
tridentate bridged Ru(II)-Pt(II) and tetrametallic multinuclear complexes were also found to have 
more robust chemical interactions with DNA than cisplatin29- 31. Multinuclear complexes have 
the potential to exhibit synergistic effects that may result in a greater impact on their target 
biological system than their mononuclear counterparts32 
 Anderson et al. have developed 
several heteromultinuclear complexes 
containing both ruthenium and platinum 
centers that have demonstrated 
antineoplastic and anti-metastatic 
potential32, 33. Na2 {trans, cis, trans- [Ru 
(III)Cl4(DMSO-S)(-µ-pyz)]2Pt(II)Cl2}, 
otherwise known as AH197, a trinuclear 
complex with characteristics of both 
NAMI and cisplatin, was shown to bind DNA with better efficacy than cisplatin33. The complex 
also demonstrated greater inhibition of cell proliferation, using a S. cervasie model system, than 
both NAMI-A and cisplatin32. Moreover, AH197 appears to be more cytotoxic than cisplatin and 
KP1019−another ruthenium centered anticancer compound, in leukemia (CCRF-CEM), NSC 
lung, breast (BT-549), and colon (COLO 205) cancer cell lines33. Although its mechanism of 
action has not been elucidated, it appears that AH197 binds RNA and terminates primer 
N N Pt Cl
N
Cl
N
Ru
Cl
ClCl
SO
Cl
RuS
Cl
Cl
Cl
Cl
O
2 Na
2
Figure 6: The chemical structure of AH19725 
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extension in in vitro reverse transcription assays by generally inhibiting DNA polymerization34. 
This suggests that AH197 targets nucleic acids much like cisplatin.  
 The Anderson lab also synthesized another 
compound, [K][RuIIICl4 (DMSO)(-µ-pyz)-PtII(DMSO-
S)Cl2], also known as IT127, a dinuclear complex which 
showed similar anticancer potential32. IT127 also has the 
ability to inhibit cell motility at a degree comparable to 
NAMI-A32. Moreover, electrophoretic mobility shift 
assays demonstrated that IT127 has a higher binding 
affinity for plasmid DNA than both cisplatin and 
AH19732.  This suggests that this hetero-multinuclear 
complex may target the nucleic acids, much like 
cisplatin, but it may inhibit metastasis in a similar manner to NAMI-A. 
 Recently, the Anderson lab developed a new class of compounds that combine the 
structure of NAMI-A with a ferrocene moiety in order to explore potential synergistic effects 
from the combination of two anti-proliferation compounds35. Hoping to combine their low 
cytotoxicity and potential selectivity for cancerous cells, these new compounds may provide 
increased DNA damage through the ferrocenium salts and antimetastatic qualities from the 
NAMI-A component of the compounds. By combining the therapeutic effects of these two 
complexes into one complex, cancer cells could be more selectively targeted and aptly combated 
with reduced side effects. Three complexes were synthesized, [Na][trans-RuCl4(dmso)(pyrdyl-
ferrocene)], [Na][trans-RuCl4(dmso)(imidazolyl-ferrocene)], and [Na][trans-RuCl4(dmso)(4 –
ferrocenoyl-pyridine)] which will be referred to as RuL1, RuL2 and RuL3 respectively35. 
Cl Pt Cl
N
N
Ru
Cl
ClCl
S
O
Cl
SO Na
Figure 7: The chemical 
structure of IT12725 
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 In electrophoretic mobility shift assays, all three compounds exhibited dose-dependent 
interactions with plasmid DNA comparable to cisplatin35. Moreover, when incubated with both 
human and bovine serum albumin proteins, all three complexes exhibited a dose-dependent 
affinity to the proteins visualized in native polyacrylamide gel electrophoresis (unpublished 
results). RuL3 in particular exhibited such a strong affinity that it appears to degrade the proteins 
after incubation at physiological temperatures36. Moreover, studies monitoring the obscuring of 
tryptophan’s fluorescent signal due to RuLX interactions with BSA showed that all three 
complexes possess interactions with the BSA proteins35. 
	  
N
N
H
Fe
Ru S
Cl Cl
Cl Cl
O
Na
O
N
Fe
Ru S
Cl Cl
Cl Cl
O Na
NO
O
NO
Fe
Ru S
Cl Cl
Cl Cl
O NaO
Figure 8: The chemical structures of the RuLX series of complexes. A) RuL1 B) RuL2 C) 
RuL327 
A) B) 
C) 
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 Due to such evidence, the RuLX compounds are fitting candidates to investigate their 
binding potential to RNA, which is similar to DNA in chemical structure, and any potential 
downstream effects that may arise. 
 
1.6. Translation inhibition as an anticancer target 
 Translation, the process in which cellular ribosomes build proteins using information 
garnered from messenger RNA, is an attractive target for cancer therapy due to its importance in 
the cell cycle. The fact that ribosomal subunits can self assemble in vitro from their constituent 
parts provided the ability to identify the roles of proteins and their processes during ribosome 
assembly and translation37. Protein synthesis takes place following assembly of both the 40S and 
60S subunits onto the mRNA, and given the presence of charged tRNAs. The process of protein 
	   	   	   	  
Cisplatin RuL2 RuL3 
	   	   	  
A) 
B) 
RuL1 RuL2 
RuL3 
Figure 9: A) Agarose (1.5%) gel electrophoresis of cisplatin, RuL1, RuL2, & RuL3 treated 
DNA (1 µg) using various concentrations of each drug. The bands were visualized using 
ethidium bromide.27 B) 8% Native-PAGE images where Bovine Serum Albumin incubated 
with RuL1, RuL2 and RuL3 in increasing concentrations28. 
RuL1 
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synthesis goes as follows: Firstly, synthesis proceeds from the N-terminus to the C-terminus of 
the protein37. Secondly, the ribosomes read the mRNA in the 5' to 3' direction. Thirdly, active 
translation occurs on polyribosomes. This means that more than one ribosome can be bound to 
and translate a given mRNA at any one time37. Finally, chain elongation occurs by sequential 
addition of amino acids to the C-terminal end of the ribosome bound polypeptide. Translation 
proceeds in an ordered process37. First, accurate and efficient initiation must first occur, only 
then can chain elongation take place and finally, accurate and efficient termination is required to 
finish the job37. 
 The initiation of translation occurs in four specific steps: first, ribosome must dissociate 
into its 40S and 60S subunits. Several initiation factors (e.g. eukaryotic translation initiation 
factor-1 [eIF-1] and eIF-3) are required to ensure that the 60S and 40S ribosomal subunits remain 
separated so that new rounds of translation can begin37. Then, the ternary complex−composed of 
GTP bound to the α-subunit of eIF2 and the initiator methionyl-tRNAmet, forms and engages the 
40S subunit37. The eIF-4F complex−the mRNA activator for translation, which comprises the 
cap-binding factor, eIF-4E, the RNA helicase eIF-4A, and the scaffold subunit eIF-4G, captures 
mRNA and brings it to the 40S subunit and the ternary complex37. The mRNA then binds to the 
ternary complex and the 60S subunit associates with the pre-initiation complex to form the 80S, 
subunit thus completing of the process of translation initiation37. This key step in translation is an 
attractive anti-proliferative target as proteins synthesis cannot take place without it correct 
completion. Moreover, the plethora of proteins that are required to modulate this process 
provides ample targets for this task. 
17 
 
 
 
 One of the most recent targeted proteins for anti-proliferative properties is the eukaryotic 
translation initiation factor 4E (eIF4-E). EIF4-E is frequently overexpressed in human cancers 
when examined in relation to disease progression38. Its overexpression also drives cellular 
transformation, tumorigenesis, and metastatic progression in experimental models. Enhanced 
eIF4E function can be caused by eIF4E overexpression, and/or activation of the ras and 
phosphatidylinositol 3-kinase/AKT pathways38. This selectively increases the translation of key 
mRNAs involved in tumor growth, angiogenesis, and cell survival. Consequently, targeting 
eIF4E for inhibition may provide an attractive therapy for many different tumor types38. This is 
because reducing eIF4E expression simultaneously and selectively reduces the expression of 
other growth and survival factors critical for malignancy38. 
 
 1.7. Silvestrol: a translation inhibiting anticancer compound 
Figure 10: Protein complexes 
in the formation of a 
eukaryotic initiation complex. 
The 3’and 5’ ends of 
eukaryotic mRNAs are linked 
by a complex of proteins that 
includes several initiation 
factors and the poly(A) binding 
protein (PAB). The factors 
eIF4E and eIF4G are part of a 
larger complex called eIF4F 
that binds to the 40S ribosomal 
subunit. 37 
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 After it was found that the 
eukaryotic translation initiation 
factor 4E (eIF4E) is overexpressed 
in clinical cases of human cancers, 
as well as tumorigenesis, and 
metastatic progression in 
experimental models, considerable 
amount of research has been conducted targeting translation initiation inhibition as anti-cancer 
therapy. It was additionally found that eIF4E cooperates with c-Myc during lymphomagenesis to 
induce drug resistance, and is a genetic modifier of the rapamycin response39. The effect of 
dysregulation of the ribosome recruitment phase of translation initiation was also found to affect 
tumor progression and chemosensitivity39. A candidate drug, Silvestrol, a compound in a class of 
natural cyclopenta[b]benzofuran flavaglines was shown to enhance chemosensitivity in a mouse 
lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN)  
inactivation or elevated eIF4E levels39.  These results establish that targeting translation initiation 
could restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity39. 
It was also shown that silvestrol is a potent anticancer compound in vivo as it inhibits the 
translation of malignancy-related mRNAs, affecting survival pathways and angiogenesis40. 
Silvestrol’s mechanism of action is said to be that it promotes the dimerization of eIF4A with 
RNA, which disrupts efficient translation initiation40. This, in turn, inhibits protein synthesis and 
as a result, disrupts tumor survival pathways. 
 The potential of heteromultinuclear metal complexes to inhibit translation inhibition has 
seldom been discussed in recent research. The unselective nature of reactivity of metal 
O O
OH3CO H
HO
CH2OH
H
OCH3
O
HO OH
OCH3
COOCH3
Figure 11: The chemical structure of Silvestrol  
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complexes with biomolecules makes metal complexes an attractive class of complexes to be 
studied for this purpose. Cisplatin has been implicated in in vitro translation inhibition by 
preventing the formation of the complete initiation complex and perhaps slowing down the 
process of chain elongation during translation17. The RuLX series of compounds have shown an 
affinity to bind both DNA and proteins, which begs the question: Do these complexes interact 
with RNA? If so, would this interaction interfere with the process of translation? 
 
1.8. Experimental overview 
 To investigate the potential binding and inhibitory effects of the RuLX series of 
compounds, a model system using dihydrofolate reductase (DHFR) plasmid DNA was 
employed. DHFR plasmid was chosen not only due to its convenience−it is the control DNA 
provided by New England Bio labs Pure Express® In Vitro Protein Synthesis kit, but also due to 
that fact that it contained all the necessary information to be transcribed into RNA and translated 
into a detectable DHFR enzyme. Once acquired, the plasmid DNA will be amplified and 
digested in preparation for its transcription into RNA. Following transcription, the binding 
affinity of RuLX series of compounds to the resultant DHFR RNA will be investigated using an 
electrophoretic mobility shift (EMSA) assay. The EMSA assay is based on the observation that 
in agarose gel electrophoresis, heavier items migrate more slowly through the gel than lighter 
items. Thus, RNA successfully bound to any of the RuLX series of compounds will migrate 
more slowly than unbound RNA and difference in electrophoretic mobility would be evident. 
Moreover, this interaction should be evident in a dose-dependent manner as the greater the 
concentration of bound drug there is, the slower RNA migration.  
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 Furthermore, downstream effects of RuLX-bound RNA will be investigated by 
comparing the translation efficiencies of DHFR RNA unexposed to the RuLX series of 
compounds versus the DHFR RNA that was exposed. Product presence will be detected using a 
DHFR assay that monitors the disappearance of NADPH, which has unique UV absorbance at 
340 nm.  DHFR catalyzes the reduction of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate utilizing 
NADPH as a cofactor.  
 
 Interestingly, within cells, this reaction is an essential step in the biosynthesis of 
nucleotide bases of DNA41. DHFR has also been considered as a target for anticancer drugs 
because its blockage in the cells causes apoptosis as a consequence of DNA synthesis 
inhibition41-43. Nevertheless, if exposure to the RuLX series of compounds prior to translation 
results in a reduction of DHFR activity, it is likely that the RuLX series of compounds can 
inhibit translation, at least in vitro. The RuLX series of complexes possess similar interactions 
with nucleic acids as ferrocenium salts and cisplatin.  Hence, it is possible that they may also 
inhibit the in vitro translation of DHFR enzyme by binding to its mRNA. 
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Figure 12: The reaction catalyzed by the enzyme dihydrofolate reductase using NADPH as its 
coenzyme. 
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2. Materials and Methods 
2.1. Experimental roadmap 
Model System: Dihydrofolate 
Reductase (DFHR) plasmid 
	  
2.1-2.3  Plasmid amplification and extraction using 
 Escherichia Coli 
2.4 Restriction digestion of extracted DHFR plasmid 
 with StuI and BamH1 enzymes 
	  
2.5 In vitro transcription of DHFR linear DNA 
	  
2.6  Incubation of DHFR RNA with RuLX Complexes 
	  
	   	  
2.7.      Binding studies of RNA and RULX 
complexes via electrophoretic mobility shift 
assay 
2.8.       In vitro translation studies 
2.9.     Detection of translation product 
using a DHFR catalyzed reaction 
2.10.     Survey of translation inhibition 
using initial reaction rates to quantify 
DHFR produced using RuLX-incubated 
RNA  
2.11.    Important Controls I: 
Quantification of DHFR 
production using RuLX-incubated 
translation machinery 
2.12.    Important Controls II: 
Quantification of DHFR activity 
using RuLX incubated with pure 
DHFR enzyme 
2.13      Follow-up studies: Inhibition of in vitro 
 translation due to RuLX-RNA interactions 
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2.2. Transformation of Dihydrofolate Reductase (DHFR) plasmid into 
competent Escherichia Coli cells 
 Zymo® Mix & Go competent cells were thawed on ice and 2 µL of Dihydrofolate 
Reductase plasmid acquired from New England Bio labs Pure Express® In Vitro protein 
synthesis kit was added to the competent cells.  After mixing gently for a few seconds 50 µL of 
the mixture was spread onto a pre-warmed (37°C) LB culture plate containing Ampicillin (100 
µg/mL). The plate was incubated at 37°C overnight. A colony was harvested from the plate and 
grown, as a starter culture, on 5 mL of LB liquid media also containing Ampicillin (100 µg/mL) 
overnight to prepare for plasmid extraction. Starter culture was diluted 1/1000 into 200 mL of 
LB ampicillin (100µg/mL) containing liquid culture. The mixture was grown at 37°C for 16 
hours shaking at 220 rpm. 
 
2.3. Plasmid Extraction of DHFR plasmid using QIAGEN Plasmid Maxi Prep 
Kit44 
 Plasmid extraction was performed according to QIAGEN instructions with the following 
modifications44. The starter culture was shaken at 220 rpm instead of the recommended 300 rpm. 
The 7th Centrifugation step was conducted for 1 hour at 4 °C, instead of the suggested 30 
minutes. The DNA was precipitated using ice-cold 100% ethanol instead of isopropanol and 
centrifuged as indicated by the QIAGEN maxi prep instructions. 
 
2.4. Restriction Digestion (RD) of 10 µg of DHFR plasmid using the 
restriction enzymes  
Table 1: Reaction Assembly of restriction digestion of 10 µg of DHFR plasmid 
 Volume (µL) 
DHFR plasmid (0.359 µg/µL) 28  
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10X NEB Buffer # 2 5 
10 U BamH1or  StuI enzyme (5 U/µL) 2 
DEPC-treated H2O 15 
Total Reaction Volume 50  
 
 The above contents were thawed on ice, assembled in a fresh microcentrifuge tube, 
mixed thoroughly, and spun down to the bottom of the tube. After which, they were incubated at 
37°C for 5 hours. The reaction products were purified using phenol chloroform extraction 
followed by ethanol precipitation. 
 Phenol: Chloroform Extraction was conducted as follows. One volume of Phenol: 
Chloroform: Isoamyl Alcohol (25:24:1) from Ambion was added to the restriction digestion 
product (50 µL). The mixture was vortexed for 30 seconds and then centrifuged for 2 minutes at 
14000 rpm (top speed) 20° C. After, the upper, aqueous phase of the mixture was extracted and 
placed in a new microcentrifuge tube where one more volume of phenol: chloroform: isoamyl 
alcohol was added. It was vortexed for one minute and spun at top speed, 20°C for 2 minutes. 
Then, the upper, aqueous phase was, once again, transferred to a fresh tube. Any transferred 
chloroform was removed by centrifugation for 10 seconds at top speed followed by removal of 
the bottom phase with a micropipette. The resultant RNA solution was precipitated using ethanol 
precipitation. 
 Ethanol precipitation was conducted as follows. 1/10th of reaction volume of 3 M sodium 
acetate (NaOAc) was added to the mixture  (for a final concentration of 0.3M NaOAc) and 
mixed thoroughly. Then, three volumes of 100% ethanol was added to the resultant mixture and 
mixed thoroughly. The mixture was placed in -80°C freezer for 1 hour (to overnight) prior to 
centrifugation. The resultant microcentrifuge tube was centrifuged at 14000 rpm, 4°C for 1 hour 
and its supernatant was discarded and the pellet was washed with 70% ethanol. After the 70% 
ethanol was discarded the tube was air dried for 10-20 minutes and then re-suspended in 30µL 
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TE buffer. A 1:25 dilution was made in TE buffer for UV quantification of RD product and a 
diagnostic 1% agarose gel comparing circular DHFR DNA and linearized DHFR product was 
also prepared to ensure proper linearization. 
 
2.5.  In Vitro Transcription (TXN) of DHFR DNA 
Table 2: Reaction assembly of a preparative scale in vitro transcription of DHFR DNA 
 Amount (µL) 
DEPC H2O 10 
10X Transcription Buffer (400 mM Tris-
HCl, 60 mM MgCl2.6H2O, 100mM DTT) 
10 
10X (25 mM) Ribonucleotides 10 
Linear DNA template (0. 976 µg/µL, 1.08 
µM) 
10 
Inorganic Pyrophosphatase (0.1 U/µL) 5 
T7 RNA Polymerase 25 
TOTAL 100 µL 
 The above ingredients were thawed on ice and assembled, as written, at room 
temperature and in a new microcentrifuge tube; the mixture was then incubated at 37 °C for 3 
hours.10U of TURBO DNase was then added to the mixture and incubated at 37°C for an 
additional 30 minutes. To stop the reaction, 5 µL of 500mM EDTA was added to the mixture 
The mixture was then purified using phenol: cholorform: isoamyl alcohol and precipitated using 
ethanol as aforementioned in the previous section. 
 
2.6.  Preparative incubation of RNA with RuLX complexes 
Table 3: Reaction assembly of preparative scale incubations of RuLX with RNA 
 0 µM 5 µM 50 µM 250 µM 500 µM 
RNA (µg/µL) 10 µL 10 µL 10 µL 10 µL 10 µL 
RuLX ---- 2 µL✪ 2 µL¤ 1 µL¢ 2 µL¢ 
TE Buffer 10 µL 8 µL 8 µL 9 µL 8 µL 
TOTAL 20 µL 20 µL 20 µL 20 µL 20 µL 
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¢ From 5 mM Stock RuLX 
¤ From 0.5 mM Stock RuLX 
✪    From 0.05 mM Stock RuLX 
 
 The above materials were incubated at 37°C for 3 hours . After incubation, the mixtures 
were aliquoted (4 aliquots of 2 µL each, 2 aliquots of 6 µL) for future translation and stored in -
80° C freezer. 
 
2.7. Binding studies of RuLX complexes with DHFR RNA using an 
 electrophoretic mobility shift assay  
 1-1.3% agarose gels were prepared where previously incubated samples (6 µL aliquots) 
were run using Bio-Rad’s Sub-Cell® agarose gel electrophoresis systems at appropriate voltages. 
 
2.8. In Vitro Translation (TSN) of DHFR plasmid 
Table 4: Reaction assembly of a representative in vitro translation (TSN) 
 Control DNA No 
Reaction 
TSN 
Solution A  5 µL 5 µL 5 µL 
Solution B  3.75 µL 3.75 µL 3.75 µL  
Nuclease-free H2O 2.75 µL 3.75 µL  2.75 µL 
Template RNA  1 µL 0 µL 1 µL 
TOTAL 12.5 µL 12.5 µL 12.5 µL 
 
 The mixture was assembled as written and incubated at 37°C for 3 hours. After 
incubation the mixture was stored in -21°C freezer until the DHFR activity assay was conducted 
 
2.9. Detection of translation product: DHFR activity assay45 
The assay was conducted following Sigma-Aldrich’s DHFR assay kit using the following 
schemes and subsequent specifications: 
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Table 5: Reaction schemes followed when using the DHFR assay 
Reaction  Assay Buffer 1x (µL) 
Sample 
 
NADPH  
(µL) 
Dihydrofolic 
Acid 
(µL) 
Blank I 984  10 µL 6  ------ 
Blank II 985  10 µL ----- 5  
DHFR 
enzyme 979  
10 µL (0.040 mg/mL) of 
DHFR enzyme 6  5  
‘No RXN’  981  6 µL of translation product without nucleic acid input 6  5  
‘Control 
DNA’  981  
6 µL of translation product 
resulting from DHFR plasmid  6  5  
‘TSN3’  981  6 µL of translation product resulting from DHFR mRNA 6  5  
 
 The Cary UV spectrophotometer was set to collect a scan ranging from 290 nm to 410 
nm, approximately every 25 seconds for five minutes. The reaction was set at 22°C using the 
block temperature control. 
 
2.10. Survey of translation inhibition: RNA and RuLX Translation Inhibition 
 Studies 
Table 5: Reaction assembly of in vitro translations used in the survey of translation inhibition: 
 0 µM 5 µM 50 µM 250 µM 500 µM 
Solution A  5 µL 5 µL 5 µL 5 µL 5 µL 
Solution B  3.75 µL 3.75 µL 3.75 µL 3.75 µL 3.75 µL 
Nuclease-free H2O 1.75 µL 1.75 µL 1.75 µL 1.75 µL 1.75 µL 
Template RNA-
RuLX  
2 µL 2 µL 2 µL 2 µL 2 µL 
TOTAL 12.5 µL 12.5 µL 12.5 µL 12.5 µL 12.5 µL 
 The mixture was assembled as written above and incubated at 37°C for 3 hours. After 
incubation the mixture was stored in -21°C freezer until ready to use in DHFR assay. A DHFR 
assay of resultant translation products of RNA-RuLX complexes was conducted using Sigma-
Aldrich Corp’s45 protocol using the following reaction schemes and subsequent changes: 
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Table 6: Reaction Schemes used in the survey of translation inhibition 
Reaction  Assay Buffer 1x (µL) 
Translation Product 
(µL) 
NADPH  
(µL) 
Dihydrofolic Acid 
(µL) 
0 µM 981  6  6  5  
5 µM 981  6  6  5  
50 µM 981  6  6  5  
250 µM 981  6  6  5  
500 µM 981  6  6  5  
 Initial studies were conducted where the Cary UV spectrophotometer was set to collect a 
scan ranging from 290 nm to 410 nm, approximately every 25 seconds for five minutes. The 
reaction was set at 22°C using the block temperature control. Subsequent studies were conducted  
where Cary UV spectrophotometer was set to collect the absorbance at 340 nm approximately 
every 12 seconds for five minutes. The reaction was set at 22°C using the block temperature 
control. 
 
2.11. Important Controls I: Quantification of DHFR production using RuLX-
 incubated translation machinery  
Table 7: Reaction assembly for incubation of RuLX complexes with ribosomal proteins 
 Control (0 µM RuLX) 80 µM RuLX 
Solution A  5 µL 5 µL 
Solution B 3.75 µL 3.75 µL 
Nuclease-free H2O 3.75 µL 0.75 µL 
Template RNA 1 µL 1 µL 
RuLX --- 2 µL 
TOTAL 13.5 µL 12.5 µL 
 The mixture, without RNA, was assembled as written and incubated at 37°C for 3 hours. 
After incubation RNA was added to the appropriate samples and set, once more at 37°C for 3 
hours. Thereafter, the mixture was stored in -21°C freezer until ready to conduct the DHFR 
activity assay. DHFR assay of resultant translation products of RuLX-incubated translation 
machinery was conducted using Sigma-Aldrich Corp’s45 protocol using the following reaction 
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schemes and subsequent changes: 
Table 8: Reaction schemes for DHFR assay of  RuLX-treated ribosomal proteins 
Reaction (rxn) Assay Buffer 1x (µL) 
Translation product 
(µL) 
NADPH  
(µL) 
Dihydrofolic Acid 
(µL) 
Control (0 µM 
RuLX) 981  6  6  5  
80 µM RuL1 981  6  6  5  
80 µM RuL2 981  6  6  5  
80 µM RuL3 981  6  6  5  
 Initial studies were conducted where the Cary UV spectrophotometer was set to collect a 
scan ranging from 290 nm to 410 nm, approximately every 25 seconds for five minutes. The 
reaction was set at 22°C using the block temperature control. Subsequent studies were conducted 
where the Cary UV spectrophotometer was set to collect the absorbance at 340 nm, 
approximately every 12 seconds for five minutes. The reaction was set at 22°C using the block 
temperature control. 
 
2.12. Important Controls II: Quantification of DHFR production using RuLX 
 incubated with pure DHFR enzyme 
Table 9: Incubation mixture assembly of RuLX complexes and DHFR enzyme 
 Control (0 µM RuLX)  80 µM RuLX 
Pure DHFR (0.40mg/mL) 6 µL 6 µL 
0.5 mM RuLX solution --- 2.4 µL 
DEPC H2O 9 µL 6.6 µL 
TOTAL 15 µL 15 µL 
 
 The above mixture was incubated at 37°C for 3 hours. It was then stored in -20°C freezer 
overnight until ready for DHFR activity assay. DHFR assay of resultant translation products of 
RNA-RuLX complexes was conducted using Sigma-Aldrich Corp’s45 protocol using the 
following reaction schemes and subsequent changes.  
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Table 10: DHFR reaction scheme for RuLX-treated enzyme 
Reaction (rxn) Assay Buffer 1x (µL) 
DHFR 
(µL) 
NADPH  
(µL) 
Dihydrofolic Acid 
(µL) 
Control (0 µM 
RuLX) 974 15 6  5  
80 µM RuL1 974 15 6  5  
80 µM RuL2 974 15 6  5  
80 µM RuL3 974  15 6  5  
 
 Initial studies were where the Cary UV spectrophotometer was set to collect a scan 
ranging from 290 nm to 410 nm, approximately every 25 seconds for five minutes. The reaction 
was set at 22°C using the block temperature control. Subsequent studies were conducted where 
the Cary UV spectrophotometer was set to collect the absorbance at 340 nm, approximately 
every 12 seconds for five minutes. The reaction was set at 22°C using the block temperature 
control. 
 
2.13. Follow-up Studies: Inhibition of in vitro translation due to RuLX-RNA 
 interactions 
 Follow-up studies were conducted using RuL2-incubated RNA in 0, 5, 50 and 250 µM 
concentrations of the drug. Triplet translations were assembled of each concentration according 
to aforementioned specifications (see Materials and Methods 2.110.). DHFR activity was 
monitored in likewise fashion. Moreover, a control measuring the effect of RuL2 incubation on 
pure DHFR enzyme was also set up in triplicate (see Materials and Methods 2.12.). DHFR 
activity was also measured for this set of experiments. 
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3. RESULTS  
 
Successful amplification of plasmid DFHR DNA, digestion of said DNA and its in vitro 
transcription established the chosen model system as a successful system to investigate 
translation inhibition. Evidence suggests that RuL2 and RuL3 have a stronger binding affinity to 
RNA than RuL1. Furthermore, all three complexes exhibited a dose-dependent reduction of 
DHFR activity. Follow-up studies, with RuL2 specifically, suggest that its inhibition may be due 
to binding to RNA, binding to the translation machinery or binding to translation product, the 
DHFR enzyme itself. Explorative controls show that RuL2 does not significantly inhibit pure 
enzyme activity or ribosomal protein activity. Thus, it is likely that RuL2 interacts with the 
mRNA is such a way that it inhibits translation of a full-length, active DHFR enzyme. 
3.1. Amplification, digestion and in vitro transcription of DHFR DNA 
 Extracted DHFR plasmid I 
Extracted DHFR plasmid II 
 
A) 
B) 
Figure 13: Representative graph of UV quantification of dilute (1:25) DHFR plasmid 
from E. coli to give the concentrations A) 0.375 µg/µL and B) 0.359 µg/µL. The fractions 
gave A260/A280 ratio of  A) 1.70 and B) 1.72 respectively.  
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 To determine whether amplification of DHFR plasmid was successful, plasmid was 
extracted from transformed E. coli cells and quantified by measuring the solution’s UV 
absorbance. It yielded two aliquots of plasmid DNA that are 0.375 µg/ µL and 0.359 µg/µL; the 
DNA was relatively pure as both aliquots had A260/A280 ratios of 1.70 and 1.72 respectively – a 
small deviation from the ideal A260/A280 of 2 (Figure. 13).  
 To check the extracted plasmid’s length and to determine success of restriction digestion, 
agarose gel electrophoresis of both circular DHFR DNA and the restriction digested DNA was 
B) A) 
2-Log Ladder 
4.0 kb 
3.0 kb 
2.0 kb 
1.5 kb 
1.0 kb 
0.9 kb 
0.8 kb 
0.5 kb 
pDHFR Linear 
DHFR 
DNA 10.0 kb  
2-Log Ladder 
5.0  kb 
4.0 kb 
3.0 kb 
2. 0 kb 
1.5 kb 
1.2 kb 
1.0 kb 
0.9 kb 
10.0  kb  
pDHFR Linear DHFR 
DNA 
Figure 14: Representative agarose gels (1.0%) comparing plasmid DHFR DNA and linearized 
DHFR DNA were visualized using ethidium bromide. Both gels were run at 100V for 1 hr. A) 
Restriction digestion of 4 µg of plasmid DHFR using BamH1 enzyme. B) Restriction digestion 
of 1 µg of plasmid DHFR using StuI enzyme 
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conducted. Gel analysis also showed appropriate bands for plasmid DHFR DNA; the band was 
near ~3000 base pairs which was congruent with the length of the DHFR plasmid which is 2879 
base pairs (Figure. 14). Dense bands evident in the plasmid DNA lane are most likely due to 
overloading of the well with DNA and perhaps some of its smearing can be attributed to the 
degradation of some of the DNA (Figure. 14A). However, once digested with StuI and purified, 
degraded DNA was discarded and the resultant linear DNA showed greater band quality when 
run on an agarose gel (Figure. 14). Furthermore, the linearized DNA migrated slightly slower 
than the plasmid DNA indicating that it is, in fact, linear (Figure 14B). Plasmid DNA migrates 
slower than linear DNA due to the superhelical tension of its confirmation.  
  
2-Log 
Ladder 
4.0 kb 
3.0 kb 
2.0 kb 
1.5 kb 
1.0 kb 
0.6 kb 
0.5 kb 
10.0 kb 
I. II. III. 
Figure 15: Diagnostic agarose gel (1.0%) 
visualized using ethidium bromide. Both 
gels were run at 100V for 1 hour I. Linear 
DHFR DNA, II. Product of In Vitro 
Transcription, and III. RNAse A-digested 
In Vitro Transcription Product. 
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 To determine the success of in vitro transcription, agarose (1%) gel electrophoresis 
comparing the linear DHFR DNA to the transcription product and to the transcription product 
digested with RNase A was performed. The success of the in vitro transcription was ascertained 
due to the fact that the transcription product showed no presence of the DHFR DNA (~3000 base 
pairs) when analyzed by agarose gel electrophoresis (Figure 15I, 15II). The presence of a strong 
band at ~500 base pairs, congruent with the length of the DHFR mRNA which is 504 bases in 
length showed successful transcription of the DHFR mRNA (Figure 15II). Moreover, the 
transcription product is successfully digested by RNase A as evidenced by the disappearance of 
the band at ~500 base pairs and the presence of digested RNA in lengths shorter than 500 base 
pairs (Figure 15III).  The mRNA product was detectable by UV and considerably pure with a 
A260/A280 ratio of 1.89 (Figure 16). 
Figure 16: Representative graph of UV detection of 0.667 µg/µL RNA at 260 nm. Its 
A260/A280 ratio was 1.89. Samples were diluted 1:25 in DEPC-treated H
2
O 
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 3.2. In Vitro Translation and detection of DHFR activity 
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 To determine whether successful translation of DHFR mRNA into an active, full-length 
DHFR enzyme occurred, three translation reactions were assembled. Each reaction contained 
either plasmid DFHR DNA obtained from the Pure Express® translation kit, 504-base DHFR 
mRNA obtained from in-house transcription, or no nucleic acid input. DHFR enzyme production 
was measured by monitoring the depletion of NADPH using its distinct absorbance at 340 nm. 
The rate of NADPH depletion is used as a quantifying reporter of the presence of full-length, 
active DHFR enzyme produced from in vitro translation. The faster the NADPH is consumed in 
the assay, the more DHFR enzyme is present in the translation product. A clear reduction in 
absorbance at 340 nm is evident from the resultant data (Figure 17). It is important to note that 
because proteins absorb at 280 nm, there is an obscuring of the signal at 340 nm by the intense 
protein absorbance resulting from not only the DHFR enzyme translated, but also from the 
ribosomal proteins responsible for the translation itself. However, the isosbestic points at ~314 
nm and ~400 nm describe a two-state process and thus an adequate measure of NADPH 
disappearance.  
Figure 17: The depletion NADPH monitored by observing decay of 340 nm peak. A) Activity 
of translation product resultant from control DHFR DNA B) Activity of translation product 
without input of nucleic acid C) Activity of translation product resultant from DHFR mRNA 
obtained from in vitro transcription. 
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 Nevertheless, a possible way to combat this obscuring of signal is to record a baseline 
correction reading using all the assay components except NADPH. A small sample of DHFR 
enzyme when measured using the aforementioned baseline correction, showed a considerable 
reduction in obscuring (Figure 18).  Unfortunately, this baseline correction proved difficult to 
reproduce during subsequent trials, and thus was abandoned. However, because our analysis 
requires only the respective initial reaction rates to report the amount of DHFR produced, 
observing the depletion in the peak at 340 nm, regardless of obscuring, is still acceptable. 
  The DHFR mRNA appears to produce less enzyme compared to the DHFR plasmid DNA 
provided by the In Vitro Translation Pure Express ® Kit. This is evident in the significant 
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Figure 18: Baseline corrected UV spectral analysis monitoring the depletion of NADPH using 
0.0040 mg/mL DHFR over 3 hours. Baseline reading was obtained from the UV analysis of all 
DHFR assay ingredients with the exception of NADPH (See Blank II of Materials and Methods 
section 2.9). 
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decrease in absorbance for the enzyme activity yielded by translating the DNA; it fell from 0.416 
to 0.260 absorbance units in 79 seconds. The enzyme activity yielded by translating DHFR 
mRNA (obtained via in-house in vitro transcription) fell from 0.684 to 0.671 in the same amount 
of time (Figure 17A, Figure 17C). This suggests that there is larger quantity of DHFR enzyme 
produced by the translation reaction using DNA provided by the kit. Since the kit can translate 
full-length proteins given either DNA or RNA as input, it possesses the ability to conduct both 
transcription and translation. It is likely that these processes are coupled48. This produces a 
greater quantity of enzyme when DNA is used48. Nonetheless, successful translation of the 
DHFR mRNA into the active enzyme indicates that the DHFR assay is still a successful model 
system to investigate the process of translation and its inhibition.  
  Measuring the inability to produce full-length product, using DHFR mRNA as our input, 
can be used as a reporting system for investigating translation inhibition. Furthermore, the Pure 
Express ® in vitro translation system is an appropriate model system to investigate translation 
inhibition due to the fact that none of the ribosomal proteins that compose the translation 
machinery consume NADPH when tested in the DHFR assay. This was ascertained by the lack 
of change when the ribosomal proteins lacking in nucleic acid input were investigated using the 
DHFR assay (Figure 17B). All in all, the DHFR enzyme activity can be used as a reporter of the 
amount of DHFR produced by the translation system because not only does Pure Express ® in 
vitro translation kit produces active DHFR detectable by a DHFR assay, but also its components 
do not consume NADPH. 
3.3. Binding studies using electrophoretic mobility shift assay 
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 To determine whether the RuLX complexes exhibit chemical interactions with RNA, 
DHFR mRNA obtained from in vitro transcription was incubated with various concentrations of 
the RuLX complexes. An electrophoretic mobility shift assay was used to visualize the chemical 
interactions resultant from the incubations. Our results suggest that RuL1 has the least interaction 
with RNA; RuL2 appears to have a more pronounced interaction, while RuL3 shows the most 
robust interaction with RNA. RuL2 and Rul3 incubated RNA showed a dose-dependent slowing 
in migration due to RNA-RuLX interactions (Figure 21).  
 In the first gel image, the difference in migration appears to be minute and the RNA 
bands migrated in smear patterns and with varying band density, both of which could be 
indicative of RNA degradation (Figure 19).  
3.0 kb 
2.0 kb 
1.5 kb 
1.0 kb 
0.5 kb 
10.0 kb  
Figure 19: Agarose (1.0%) gel electrophoresis of RuL1, RuL2, & RuL3 treated RNA (3 µg) 
with increasing concentrations of each drug: 5, 50, 250, 500 µM. RNA was incubated with 
RuLX complexes for 3 hours. Gel was run at 100V for 1 hour. 
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 For the next set of experiments, a new transcription of RNA was carried out and 
incubated with the RuLX complexes for half the duration (1.5 hours) in hopes of alleviating 
degradation effects. The incubation mixture was run on an agarose gel at the same voltage and 
time as the previous experiments (Figure 20). These results show that while the RNA bands ran 
with constant density, the smearing persisted. This smearing is likely an artifact of the phenol-
chloroform purification process where some of the RNA may have underwent phenol 
contamination and as a result, degraded (Figure. 20). Nonetheless, the migratory pattern persisted 
where RuL2 and RuL3 show the most promising interactions with RNA (Figure 20). Moreover, 
for better resolution, the experiment was repeated using higher percentage agarose (1.3%) and 
using the revised RNA and RuLX complex incubation time of 1.5 hours. The gel was also run 
for a longer time (4.5 hours) and at a lower voltage to ensure that heat generated from the 
electrophoresis apparatus did not impair any RuLX-RNA interactions (Figure 21). The resultant 
gel showed a step-wise slowing in migration from 50-200 µM concentrations of RuL2 and RuL3.  
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Figure 20: Agarose (1.0%) gel electrophoresis of RuL1, RuL2, & RuL3 treated, newly 
transcribed RNA (3 µg) using increasing concentrations of each drug: 5, 50, 250, 500 µM. 
RNA was incubated with RuLX complexes for 1.5 hours. Gel was run at 100V for 1 hour. 
40 
 
RuL1 did not show a slowing in migration of RNA even at this higher resolution (Figure 21). 
From the evidence garnered, it is likely that RuL2 and RuL3 are the only complexes possessing 
strong enough chemical interactions with RNA to survive agarose electrophoresis.  It is possible 
that RuL2 and RuL3 form covalent adducts with the mRNA; however mass spectrometry studies 
are needed to confirm this hypothesis. 
 
 
 RuL2- and RuL3-dependent slowing of RNA migration in agarose gel electrophoresis 
may be due to their distinct chemical structure as compared to RuL1. RuL2 and RuL3 both 
contain an ether moiety that bridges the NAMI-A-like and the ferrocene-like elements of their 
structures, while RuL1 possesses an amine group in that location (Figure 8). This could yield 
unique possibilities of reactivity for the RuL2 and RuL3 complexes that may not be available for 
the RuL1 complex.  Anti-cancer compounds like Bisulfan are DNA alkylators containing the 
ether moieties that cause intrastrand cross-links between guanine bases in DNA double-helix 
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Figure 21: Agarose (1.3%) gel electrophoresis of RuL1, RuL2, & RuL3 treated RNA (2 µg) 
using increasing concentrations of each drug: 5, 50, 250, 500 µM. RNA was incubated with 
RuLX complexes for 1.5 hours. Gel was run at 50V for 4.5 hours. 
41 
 
strands, directly attacking DNA46. RuL2 and RuL3’s superior interaction with RNA compared to 
RuL1 could be due to similar alkylating mechanisms with RNA. 
 Furthermore, RuL2 contains an imidazole moiety that has been shown to favor reactivity 
with nucleic acids. The imidazole ring has been shown to be extremely reactive with biological 
molecules, in the reactivity it possesses especially as an integral component of the amino acid 
histidine, and its biological reactions. Moreover, imidazole’s antiproliferative and antimetastatic 
contributions are evident in the success of NAMI-A as a candidate drug.  
 However, the nature of the RNA-RuLX interactions remains unclear. It is possible that 
the interactions are covalent due to the stability of RuLX-RNA interactions under the pressure of 
agarose gel electrophoresis. However more rigorous methods of study are needed to provide 
evidence for this. Particularly, inductively coupled plasma mass spectrometry and matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry experiments 
can shed great insight into these interactions. Using the aforementioned studies, NAMI-A was 
found to form adducts with RNA at comparable frequencies to which it forms adducts with 
DNA47. Moreover, MALDI-TOF studies also showed that when interacting with nucleic acids, 
NAMI-A bound to oligonucleotides with strong coordination with either a single ruthenium atom 
or a ruthenium atom linked to an imidazole ring47. It could be possible that the NAMI-A-like 
portion of the RuLX complex coordinates with RNA using similar mechanisms. Mass 
spectrometry studies can reveal more about the nature of these interactions than gel 
electrophoresis. 
 
3.4. Survey of RuLX inhibition of RNA directed in vitro translation 
42 
 
 
 
A) 
B) 
C) 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 µM 5 µM  50 µM  250 µM  500 µM  
N
or
m
al
iz
ed
 R
ea
ct
io
n 
R
at
e 
to
 0
 µ
M
  R
uL
1 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0  µM  5  µM  50  µM  250  µM  500  µM  
N
or
m
al
iz
ed
 R
ea
ct
io
n 
R
at
e 
to
 0
 µ
M
  R
uL
2 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0  µM 5  µM  50  µM  250  µM  500  µM  
N
or
m
al
iz
ed
 R
ea
ct
io
n 
R
at
e 
to
 0
 µ
M
  R
uL
3 
Figure 22: A survey of RuLX translation inhibition. Normalized rate of reaction of in vitro 
translation product using A) RuL1-treated RNA B) RuL2-treated RNA C) RuL3-treated RNA 
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 To explore the inhibitory effects of the RuLX compounds during in vitro translation, a 
series of translation reactions were prepared using DFHR mRNA incubated with varying 
concentrations of RuLX complexes. Thereafter, their translation products were examined using a 
DHFR activity assay. The results of these studies suggest that there is a dose-dependent 
inhibition of translation for all three complexes (Figure 22).  
 RuL1-treated RNA shows a significant reduction in DHFR activity at a concentration of 
250 µM and onwards, with a reduction of over half the activity when compared to translation 
using untreated RNA (Figure. 22). It also shows a counter-intuitive spike at concentrations of 5 
µM and 500 µM RuL1 (Figure 22A). It seems as though there is more activity from DHFR 
resultant from RNA treated with 5 µM RuL1 than untreated RNA (Figure. 22A). This is likely a 
result of an experimental error; the experiment should be repeated multiple times to remedy this.  
Similarly, it seems as though there is slightly more enzyme activity of DHFR translated from 
RNA treated with 500 µM RuL2 than with RNA treated with 250 µM RuL2 (Figure 22B). This 
is likely an artifact to the natural variability of the translation machinery. Although incubated 
with the same components, in each new translation event, the translation machinery produces 
varying amounts of DHFR RNA. This was demonstrated in that different translation events with 
untreated RNA set up on the same day resulted in varied enzyme activity profiles. Moreover, it 
could be that at 250 µM, all the possible sites of interaction on the DHFR mRNA are occupied; 
this could be the concentration at which the DHFR mRNA is saturated with RuLX complexes. 
Nevertheless, a more statistically robust exploration of the enzyme activity yielded from the 
translation of RuL2-treated RNA is needed to account for variability of the translation output and 
assign statistical significance to the trend.  
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 RuL2-treated RNA shows a plunge in DHFR activity at concentrations as low as 50 µM, 
where there is less than half of the activity compared to untreated RNA (Figure 22B). The 
reduction in activity appears to be dose-dependent, with the 250 µM having only a 1/5th of the 
activity that DHFR produced from untreated RNA has (Figure 22B). Likewise, RuL3 shows a 
significant reduction in DHFR activity by 50 µM, where there is a 40% reduction in DHFR 
activity (Figure 22C). Dose-dependency is evident because enzyme activity decreases as the 
concentration of RuLX complexes increases (Figure 22C). However, more statistically robust 
explorations of these interactions are needed to assign statistical significance to the inhibition 
and to establish the concentration at which there is a significant reduction in activity for each 
complex. This would provide insight as to which complex is more effective at inhibiting RNA 
driven in vitro translation. 
3.5. Important controls to investigate nature of the translation inhibition 
 
 
 To ensure that the inhibition measured by the depletion of NADPH is due to the 
impairment of translation by RNA-RuLX interactions, two controls were designed to tackle 
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Figure 23: Important controls to investigate the nature of inhibition A) Enzyme activity of 
ribosomal proteins with 80 µM of RuLX complexes and supplied with DHFR mRNA for 
translation B) Activity of DHFR enzyme incubated with 80 µM of RuLX complexes. 
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potentially confounding interactions between the RuLX complexes and proteins. Due to the fact 
that previous work has shown that the RuLX complexes can chemically interact with both DNA 
and proteins, it is important to establish a control to ensure that the reduction of enzyme activity 
is not due to RuLX interactions with the ribosomal proteins or RuLX-induced impairment of 
successfully translated, active, full-length DHFR.  
  To investigate whether the RuLX complexes inhibit efficient translation by impairing the 
ribosomal proteins, ribosomal proteins were incubated with the highest exposure of RuLX 
complexes for 3 hours and used in translation reactions that utilized clean DHFR mRNA as their 
input. The highest exposure of RuLX to the ribosomal proteins was calculated to be 80 µM, 
which corresponds to 500 µM RuLX-treated RNA.  This is because when the RuLX-treated 
RNA is entered into the translation reaction assembly, the overall concentration of RuLX 
complexes exposed to the ribosomal proteins is diluted. The results of this survey suggest that 
the complexes do interact with the translation machinery inhibiting efficient translation in an 
unidentified fashion (Figure 23A). After incubation with all three complexes, RuL1 and RuL2 
exhibit half the rate of NADPH consumption of the DHFR obtained un-incubated translational 
machinery. RuL3 shows the most significant reduction of DHFR activity and thus, it is likely 
that it is the mechanism that contributes the bulk of the inhibitory effects of the complex (Figure 
23A). However, due to minimal materials and lack of time only an exploratory investigation of 
these effects was conducted; a more robust investigation of the complexes is needed to delineate 
not only whether the contribution of RuLX interactions with the ribosomal proteins is 
statistically significant, but also whether it is responsible for the bulk of observed translation 
inhibition. 
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  To investigate whether the RuLX complexes inhibit efficient translation by binding to 
available, full-length DHFR, DHFR enzyme purchased form Sigma- Aldrich was treated with 
RuLX complexes at the highest exposure (80 µM) and its activity was measured using a DHFR 
assay (Figure 23B). The resultant data follows that RuL1-treated DHFR has similar activity to 
untreated DHFR. RuL2 and RuL3 appear to reduce the activity of DHFR due to their interactions 
with the enzyme. RuL2-treated DHFR has 20% less activity; it is possible that this small 
reduction activity may be insignificant when compared to untreated DHFR. More statistically 
robust experiments are needed to ensure this. Moreover, RuL3-treated DHFR consumes NADPH 
at half the rates that untreated DHFR does (Figure 23B). Such a significant reduction in activity 
could be indicative of such a vigorous interaction with the RuL3 complex that it degrades the 
DHFR enzyme. However, due to minimal materials and lack of time, only an exploratory 
investigation of these effects was conducted. A more robust investigation of the complexes is 
needed to delineate whether the contribution of RuLX interactions with active DHFR is 
statistically significant and whether it is responsible for the bulk of the inhibition of translation. 
3.6. Follow-up studies investigating the impact and mechanism of RNA-RuL2 
interactions in in vitro translation 
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 Due to the lack of significant agarose gel mobility changes in RuL1-treated RNA and the 
significant reduction of activity when the RuL3-treated DHFR enzyme, RuL1 and RuL3 
complexes were not investigated for further triplicate studies. RuL2, due to its prevalent mobility 
shift in EMSA and seemingly minimal interaction with free DHFR enzyme, was selected for 
further analysis.  
 To follow-up on RuL2’s ability to inhibit translation, triplicate translation events with 
RuL2-incubated RNA were carried out and their translation product measured for DHFR 
activity. While a dose-dependent trend is observed with regards to the reduction in DHFR 
activity, statistical analysis does not find them to be different from the activity of DHFR 
produced from untreated RNA or from each other [ANOVA p=0.321] (Figure 24B). Moreover, a 
control to rule out interactions between RuL2 and full-length DHFR as the source for the bulk of 
the inhibition was also conducted. Its results show that although there is a reduction in activity 
due to RuL2 interactions with the enzyme, the reduction appears statistically insignificant [t-test 
p= 0.287] (Figure 24B). In other words, the activity of untreated DHFR is essentially the same as 
the activity of RuL2-treated DHFR. Nevertheless, a more robust analysis of the inhibitory effects 
is needed due to the variability of the translation environment. An increase in replicates, from 3 
to >5, could give data that is more insightful under statistical analysis. Moreover, outliers can 
more easily be singled out when a larger sample size is available. While RuL2 shows a dose-
dependent reduction in enzyme activity when incubated with its DHFR mRNA, it is unlikely due 
to RuL2 impairing the activity of fully translated DHFR. However, it could be due to RuL2 
Figure 24: RuL2 dependent translation inhibition. A) Rate of consumption NADPH of DHFR 
compared to DHFR incubated with 80 µM RuL2. t-test  p>0.05 B) Normalized reaction rates 
(to those of 0 µM incubation) of in vitro translation product obtained with RuL2-treated RNA. 
ANOVA p>0.05 
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impairment of the ribosomal proteins. This may account for some of the reduction in DHFR 
activity. However, due to minimal materials and lack of time, only an exploratory investigation 
of these effects was conducted. The data gathered so far, suggest that RuL2-dependet translation 
inhibition may be due to its interaction with the mRNA. 
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4. DISCUSSION 
 The explorative results obtained suggest that the RuLX complexes interact with both 
nucleic acids and proteins. They also show that treating RNA with the RuLX can inhibit mRNA 
directed in vitro translation. The data also suggest that the manner by which translation is 
inhibited, is different for each RuLX compound. Although the mechanism responsible for the 
bulk of the inhibition for each compounds is still unclear, more robust and specific experiments 
can be conducted in the future to reveal this relationship.  
 These in vitro studies show promising results where these complexes show chemical 
interactions with RNA and proteins. This allows for multiple avenues for inducing apoptosis 
when entered into cells. Moreover, the unique reactivity of the ruthenium and iron metal centers 
provides all three complexes with the potential to be selective against cancerous cells. 
Ruthenium (III) requires activation by reduction that is more likely in the acidic 
microenvironment of the tumor cells. Likewise, the ferroccene moiety can interconvert between 
its inert state and its active ferrocenium form depending on the redox potential of the tumor 
microenvironment. To support these findings, in vivo analyses of these complexes should be 
carried out in human cancerous cultures or tractable cancer model systems like Saccharomyces 
cerevisiae. An investigation of their antiproliferative properties as well as an analysis on their 
accumulation within the cell is needed.  
4.1 Study design limitations 
 It is important to note the limitations of the current study design, which uses the reduction 
of enzyme activity as a measure of translation inhibition. This design does not reveal what aspect 
of translation is affected or impaired by the RuLX complexes. Whether incubation with RuLX 
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complexes inhibits translation initiation, which would result in no protein production, or cause 
early termination of translation, which would give truncated, inactive DHFR enzyme, cannot be 
determined using the current study design. Either of the aforementioned translation inhibition 
events would result in identical reduction of enzyme activity.  
 To remedy this, experiments investigating the inhibition of peptide synthesis using either 
35S labeled methionine or fluorescently labeled lysine should be conducted. Both labels are easily 
visualized using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The 
canonical sequence of DHFR possesses seven methionine residues and nineteen lysine residues 
suggesting that both labeling techniques would yield observable amplification of signal49. 
Moreover, the labeling can held delineate what aspect of translation is inhibited. If the RuLX 
complexes interfere with translation initiation, then there would be no successful peptide 
synthesis and thus no detection of peptides when examined using SDS-PAGE. On the other 
hand, if the interactions between the RuLX complexes and RNA cause a termination of 
translation, peptide chains smaller than 21 kDa (the molecular weight of the DHFR enzyme) 
would be observed using SDS-PAGE analysis. In the event that any of the RuLX complexes 
cause termination, peptide-sequencing studies should be carried out uncover the amino acid 
residues where termination frequently occurs. This could reveal more details of the downstream 
consequences of RNA and RuLX interactions.   
4.2. RuL1 
 RuL1 possessed little to no interaction with RNA when examined by agarose gel 
electrophoresis. It is likely that the interaction between RuL1 and RNA, if any, is non-covalent. 
It would then be unlikely for this complex to inhibit translation by forming chemical interactions 
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with the RNA. It is important to note though, that the complex displayed translation inhibition in 
concentrations greater than 250 µM. The mechanism of this inhibition is unlikely to be through 
RNA-RuL1 interactions. However, it may be due to the complex’s protein-RuL1 interactions. 
When investigated with DHFR enzyme and the translation machinery, RuL1 could impair the 
activity of both enzymes suggesting that its molecular target may be proteins rather than nucleic 
acids. In vivo studies investigating the binding affinity RuL1 to protein complexes are needed to 
ascertain the aforementioned hypothesis. 
4.3. RuL2 
 RuL2 seems to be the most promising of the complexes as it not only possesses an 
interaction with RNA visible through an agarose EMSA, but also because it inhibits translation 
at a lower concentration than its counterpart RuL1. RuL2 inhibits translation at similar 
concentrations to RuL3. ICP-MS or MALDI-TOF analysis on the nature of the RNA-RuL2 
interactions is needed to determine whether they are covalent. Also, such studies may provide 
evidence as to whether its imidazole moiety contributes to its reactivity with RNA, as NAMI-A’s 
imidazole moiety does. Nevertheless, the strength RNA-RuL2 interactions may cause 
cytotoxicity in an in vivo model.  Moreover, RuL2 appears to be able to weaken both DHFR and 
ribosomal protein activity, thus providing more evidence that RuL2 is capable of binding 
proteins. It could be the synergistic effects of both bonding to RNA and to proteins that allow 
this complex to inhibit translation at a concentration of 50µM.  
4.4. RuL3 
 RuL3 appears to be the most potent of the three complexes. Not only does it have a more 
pronounced mobility shift when investigating its interactions with RNA, but it also shows a 
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considerable ability to hinder both DHFR activity and efficient translation by the ribosomal 
proteins when in incubated with them. Its interaction with RNA may allow for increased 
cytotoxicity (compared to RuL1 and RuL2) in an in vivo model. Moreover, its ability to 
significantly handicap protein activity is congruent with the EMSA evidence that suggested that 
RuL2 might be able to degrade proteins (Figure.8). In vivo analyses could further elaborate on 
RuL3’s antiproliferative potential. 
4.5. Future Experiments 
 Inductively coupled plasma mass spectrometry and matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry experiments should be 
conducted to reveal the nature of the RNA-RuLX interactions. Moreover, studies investigating 
the RuLX complexes binding affinity to DNA and RNA in the presence and absence of the 
reductant ascorbate should be carried out to investigate the activation by reduction hypothesis. 
These interactions should be characterized by both gel analysis and MALDI-TOF experiments. 
Hostetter and colleagues found that Ru-nucleotide interactions, in the context of NAMI-A and 
oligonucleotide biding, increase significantly in the presence of ascorbate. Furthermore, studies 
to determine whether ascorbate discourages the interconversion between ferroccene and 
ferrocenium salts of the RuLX complexes should also be conducted47. This is because, while 
ruthenium (II) is reduced to its active form ruthenium (II), ferroccene, wielding Fe (II), needs to 
be oxidized to its ferrocenium salt derivative, Fe (III), to possess antineoplastic and anti 
proliferative properties27, 47. 
 To determine whether the inhibitory effects of RuLX are broad-range or specific to the 
DHFR mRNA, equivalent translation inhibition studies using β-galactosidase, luciferase or green 
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fluorescent protein mRNA as a new model should be conducted. All three aforementioned 
enzymes have established activities that are easily detected by their respective enzyme activity 
assays.  
4.6. Concluding Remarks 
 It is evident from our studies that all three complexes possess the potential to inhibit 
translation. However, due to the differing strength of interactions with RNA, it is likely that these 
complexes inhibit translation through different mechanisms. More statistically robust studies 
could reveal whether these complexes inhibit translation primarily by binding to RNA or by 
denaturing proteins. An investigation on the antiproliferative and antineoplastic potential of the 
RuLX complexes should be conducted in tractable cancer model systems like Saccharomyces 
cerevisiae. Nevertheless, these complexes possess great potential to inhibit translation and 
become a possible addition into the arsenal of metal-centered chemotherapeutic complexes. 
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